Top

BMC Complementary Medicine and Therapies

Published in:

Open Access 01-12-2021 | Escherichia Coli | Research article

The beneficial effects of the composite probiotics from camel milk on glucose and lipid metabolism, liver and renal function and gut microbiota in db/db mice

Authors: Tabusi Manaer, Lan Yu, Xin-Hua Nabi, Dinareer Dilidaxi, Lu Liu, Jialehasibieke Sailike

Published in: BMC Complementary Medicine and Therapies | Issue 1/2021

Abstract

Background

Probiotics may have beneficial effects on patients with type 2 diabetes mellitus (T2DM). We separated 4 lactobacillus and 1 saccharomycetes from traditional fermented cheese whey (TFCW) and prepared composite probiotics from camel milk (CPCM) and investigated their effects on glucose and lipid metabolism, liver and renal function and gut microbiota in db/db mice.

Methods

CPCM was prepared in the laboratory and 40 db/db mice were randomly divided into 4 groups as metformin, low-dose and high-dose group and model group, and treated for 6 weeks. In addition, 10 C57BL/Ks mice as normal control group were used for comparison. Fasting blood glucose (FBG), body weight (BW), oral glucose tolerance test (OGTT), glycated hemoglobin (HbAlc), C-peptide (CP), triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), 24 h urinary microalbumin (24 h malb), urine ketone, urine sugar, pancreas and liver tissue and intestinal flora were tested.

Results

Compared to diabetic group, high dose CPCM significantly decreased FBG, OGTT, HbAlc and IRI, plasma TC, TG, LDL-C, 24 h malb, urine ketone and urine sugar, increased CP, HDL-C levels, improved the liver and kidney function, protected the function of islets, also increased intestinal tract lactic acid bacteria and Bifidobacterium, decreased Escherichia in db/db mice.

Conclusion

CPCM decreased FBG, OGTT and HbAlc, increased CP, modulated lipid metabolism and improved liver and kidney protected injury in db/db mice, which may be related to various probiotics acting through protecting the function of islets and regulating intestinal flora disturbance.

Available only for authorised users

Lakerveld J, Bot SDM, Chinapaw MJ, van Tulder MW, van Oppen P, Dekker JM, et al. Primary prevention of diabetes mellitus type 2 and cardiovascular diseases using a cognitive behavior program aimed at lifestyle changes in people at risk: design of a randomized controlled trial. BMC Endocr Disord. 2008;8(1):6. https://doi.org/10.1186/1472-6823-8-6.CrossRefPubMedPubMedCentral

Xu Y, Wang L, He J, Bi Y, Li M, Wang T, et al. Prevalence and control of diabetes in Chinese adults. JAMA. 2013;310(9):948–59. https://doi.org/10.1001/jama.2013.168118.CrossRefPubMed

International Diabetes Federation. IDF Diabetes Atlas. 2019. https://www.idf.org/aboutdiabetes/what-is-diabetes/facts-figures.html. Accessed 20 Dec 2020.

Herring R, Jones RH, Russell-Jones DL. Hepatoselectivity and the evolution of insulin. Diabetes Obes Metab. 2014;16(1):1–8. https://doi.org/10.1111/dom.12117.CrossRefPubMed

Yan W, Yang X, Zheng Y, Ge D, Zhang Y, Shan Z, et al. The metabolic syndrome in Uygur and Kazak populations. Diabetes Care. 2005;28(10):2554–5. https://doi.org/10.2337/diacare.28.10.2554.CrossRefPubMed

Wang L, Tao Y, Xie Z, et al. Prevalence of metabolic syndrome, insulin resistance, impaired fasting blood glucose, and dyslipidemia in Uygur and Kazak populations. J Clin Hypertens (Greenwich). 2010;12:741–5.CrossRef

Li N, Wang H, Yan Z, et al. Ethnic disparities in the clustering of risk factors for cardiovascular disease among the Kazakh, Uygur, Mongolian and Han populations of Xinjiang: a cross-sectional study. BMC Public Health. 2012;12:499.CrossRef

Zhang HW, Jiang S, Xu YC. A cross-sectional study on serum uric acid level and the distribution of metabolic syndrome among Uigur, Han and Kazak prediabetic groups in Xinjiang. Chin J Epidemiol. 2013;34:958–60.

Yan WL, Li XS, Wang Q, Huang YD, Zhang WG, Zhai XH, et al. Overweight, high blood pressure and impaired fasting glucose in Uyghur, Han, and Kazakh Chinese children and adolescents. Ethn Health. 2015;20(4):365–75. https://doi.org/10.1080/13557858.2014.921894.CrossRefPubMed

10.

NaBi XH, Rehemu N, Luo L, et al. Effects of traditional fermented cheese whey on experimental atherosclerosis in rats. Chin J New Drugs. 2007;16:1776–9.

11.

NaBi XH, Ma CY, Manaer T, et al. Anti-atherosclerotic effect of traditional fermented cheese whey in atherosclerotic rabbits and identification of probiotics. BMC Complement Altern Med. 2016;16(1):309. https://doi.org/10.1186/s12906-016-1285-8.CrossRefPubMedPubMedCentral

12.

Wang JM, Zhao RG, Xiao DG. Primary Study on Lactobacillus casei Starter Powder with High Activity. J Univ Sci Technol tianjin. 2005;20:9–13.

13.

Nagata S, Asahara T, Ohta T, Yamada T, Kondo S, Bian L, et al. Effect of the continuous intake of probiotic-fermented milk containing Lactobacillus casei strain Shirota on fever in a mass outbreak of norovirus gastroenteritis and the faecal microflora in a health service facility for the aged. Br J Nutr. 2011;106(4):549–56. https://doi.org/10.1017/S000711451100064X.CrossRefPubMed

14.

Musso G, Gambino R, Cassader M. Obesity, diabetes, and gut microbiota the hygiene hypothesis expanded? Diabetes Care. 2010;33:2277–84.CrossRef

15.

Larsen N, Vogensen FK, van den Berg FW, et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One. 2010;5(2):e9085. https://doi.org/10.1371/journal.pone.0009085.CrossRefPubMedPubMedCentral

16.

Wang M, Bi J. Medium optimization for kefiran synthesis by Lactobacillus kefiranofaciens. Indus Microbiol. 2007;37:36–40.

17.

Zhou J, Zheng M. Malleable protein matrix and contact dermatitis. Inter J Dermatol Venereol. 2009;35:222–4.

18.

Wang J. Progress of physiological function of lactic acid bacteria. Food Ferment Sichuan. 2005;41:43–6.

19.

Liu SM, Man CX, Li L, Jiang YJ. Research on Immunomodulatory of lactic acid Bacteria. Chin J Food Nutr. 2013;4:60–3.

20.

Liu AG, Liu YL, Wang ZJ, et al. Molecular identification of wild wine-related yeasts isolated from spontaneous wine fermentation in Ningxia district. J Northwest Univ (Natural Science Edition). 2008;36:203–7.

21.

Wang ZJ, Liu YL, Liu AG, et al. Survey on yeast population dynamics during wine spontaneous fermentation in Xinjiang. J Agr Univ Huazhong. 2008;27:664–7.

22.

Latipa A, Xue T, Xin-Hua N. Molecular biological identification of one lactic acid bacteria in Xinjiang traditional fermented camel milk. J Med Univ Xinjiang. 2014;34(2):155–9.

23.

Manaer T, Yu L, Zhang Y, Xiao XJ, Nabi XH. Anti-diabetic effects of shubat in type 2 diabetic rats induced by combination of high-glucose-fat diet and low-dose streptozotocin. J Ethnopharmacol. 2015;169:269–74. https://doi.org/10.1016/j.jep.2015.04.032.CrossRefPubMed

24.

Dinareer D, Lu L, Jialehasibieke S, et al. Probiotic characteristics of the lactic acid bacteria and yeasts in Xinjiang-traditional fermented dairy products. China Microecology. 2018;30:5–9 13.

25.

Jialehasibieke S, Xin S, Amanguli J, et al. Probiotic characteristics of probiotics in Xinjiang traditional fermented dairy products. China Microecology J. 2019;31:502–8.

26.

Wang Y, Dinareer D, Wu Y, et al. Composite probiotics alleviate type 2 diabetes by regulating intestinal microbiota and inducing GLP-1 secretion in db/db mice. Biomed Pharmacother. 2020;125:109914. https://doi.org/10.1016/j.biopha.2020.109914.CrossRefPubMed

27.

Hendijani F, Akbari V. Probiotic supplementation for management of cardiovascular risk factors in adults with type II diabetes: a systematic review and metaanalysis. Clin Nutr. 2018;37(2):532–41. https://doi.org/10.1016/j.clnu.2017.02.015.CrossRefPubMed

28.

Teng Y, Li D, Guruvaiah P, Xu N, Xie Z. Dietary supplement of large yellow tea ameliorates metabolic syndrome and attenuates hepatic Steatosis in db/db mice. Nutrients. 2018;10(1):75. https://doi.org/10.3390/nu10010075.CrossRefPubMedCentral

29.

Yoo JY, Kim SS. Probiotics and prebiotics: present status and future perspectives on metabolic disorders. Nutrients. 2016;8(3):173. https://doi.org/10.3390/nu8030173.CrossRefPubMedPubMedCentral

30.

Singh S, Sharma RK, Malhotra S, Pothuraju R, Shandilya UK. Lactobacillus rhamnosus NCDC17 ameliorates type-2 diabetes by improving gut function, oxidative stress and inflammation in high-fat-diet fed and streptozotocintreated rats. Benef Microbes. 2017;8(2):243–55. https://doi.org/10.3920/BM2016.0090.CrossRefPubMed

31.

Payne AN, Chassard C, Zimmermann M, et al. The metabolic activity of gut microbiota in obese children is increased compared with normal-weight children and exhibits more exhaustive substrate utilization. Nutr Diabetes. 2011;18:e12.CrossRef

32.

Mekkes MC, Weenen TC, Brummer RJ, et al. The development of probiotic treatment in obesity: a review. Benef Microbes. 2014;5:19–28.CrossRef

33.

Allen TJ, Cooper ME, Lan HY. Use of genetic mouse models in the study of diabetic nephropathy. Curr Diab Rep. 2004;4:435–40.CrossRef

34.

Chen WX. Standardization of glycated hemoglobin measurement. Chin J Diabetes. 2011;19:803–4.

35.

Le TK, Hosaka T, Nguyen TT, et al. Bifidobacterium species lower serum glucose, increase expressions of insulin signaling proteins, and improve adipokine profile in diabetic mice. Biomed Res. 2015;36(1):63–70. https://doi.org/10.2220/biomedres.36.63.CrossRefPubMed

36.

Falcinelli S, Picchietti S, Rodiles A, Cossignani L, Merrifield DL, Taddei AR, et al. Lactobacillus rhamnosus lowers zebrafish lipid content by changing gut microbiota and host transcription of genes involved in lipid metabolism. Sci Rep. 2015;5(1):9336. https://doi.org/10.1038/srep09336.CrossRefPubMedPubMedCentral

37.

Mohammadi Sartang M, Mazloomi SM, Tanideh N, et al. The effects of probiotic soymilk fortified with Omega-3 on blood glucose, lipid profile, Haematological and oxidative stress, and inflammatory parameters in Streptozotocin Nicotinamide-induced diabetic rats. J Diabetes Res. 2015;2015:696372.CrossRef

38.

Ebrahimi ZS, Nasli-Esfahani E, Nadjarzade A, et al. Effect of symbiotic supplementation on glycemic control, lipid profiles and microalbuminuria in patients with non-obese type 2 diabetes: a randomized, double-blind, clinical trial. J Diabetes Metab Disord. 2017;16(1):23. https://doi.org/10.1186/s40200-017-0304-8.CrossRefPubMedPubMedCentral

39.

Yadav H, Jain S, Sinha PR. Antidiabetic effect of probiotic dahi containing Lactobacillus acidophilus and Lactobacillus casei in high fructose fed rats. Nutrition. 2007;23(1):62–8. https://doi.org/10.1016/j.nut.2006.09.002.CrossRefPubMed

40.

Bo H, Huang SM, Wu WH, et al. Status quo of diabetic nephropathy and countermeasures. Chin J Nephrol. 2011;27:464–5.

41.

Xiao L, Sun L, Liu FY. New progress in the formation of proteinuria in diabetic kidney disease. Chin J Nephrol. 2010;26:478–80.

42.

Tesch GH, Lim AK. Recent insights into diabetic renal injury from the db/db mouse model of type 2 diabetic nephropathy. Am J Physiol Renal Physiol. 2011;300(2):F301–10. https://doi.org/10.1152/ajprenal.00607.2010.CrossRefPubMed

43.

Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444(7122):1027–31. https://doi.org/10.1038/nature05414.CrossRefPubMed

44.

Jia W, Li H, Zhao L, Nicholson JK. Gut microbiota: a potential new territory for drug targeting. Nat Rev Drug Discov. 2008;7:123–9.CrossRef

45.

Gomes AC, Bueno AA, de Souza RG, et al. Gut microbiota, probiotics and diabetes. Nutr J. 2014;13(1):60. https://doi.org/10.1186/1475-2891-13-60.CrossRefPubMedPubMedCentral

46.

Everard A, Matamoros S, Geurts L, et al. Saccharomyces boulardii administration changes gut microbiota and reduces hepatic steatosis, low-grade inflammation, and fat mass in obese and type 2 diabetic db/db mice. MBio. 2014;5:e01011–4.CrossRef

47.

Candela M, Biagi E, Soverini M, Consolandi C, Quercia S, Severgnini M, et al. Modulation of gut microbiota dysbioses in type 2 diabetic patients by macrobiotic Ma-pi 2 diet. Br J Nutr. 2016;116(1):80–93. https://doi.org/10.1017/S0007114516001045.CrossRefPubMedPubMedCentral

48.

Chen F, Wen Q, Jiang J, Li HL, Tan YF, Li YH, et al. Could the gut microbiota reconcile the oral bioavailability conundrum of traditional herbs? J Ethnopharmacol. 2016;179:253–64. https://doi.org/10.1016/j.jep.2015.12.031.CrossRefPubMed

49.

Bordalo Tonucci L, Dos Santos KM, De Luces Fortes Ferreira CL, et al. Gut microbiota and probiotics: focus on diabetes mellitus. Crit Rev Food Sci Nutr. 2017;57(11):2296–309. https://doi.org/10.1080/10408398.2014.934438.CrossRefPubMed

50.

Amar J, Serino M, Lange C, et al. Involvement of tissue bacteria in the onset of diabetes in humans: evidence for a concept. Diabetologia. 2011;54(12):3055–61. https://doi.org/10.1007/s00125-011-2329-8.CrossRefPubMed

51.

Nova E, Pérez de Heredia F, Gómez-Martínez S, et al. The role of probiotics on the microbiota: effect on obesity. Nutr Clin Pract. 2016;31(3):387–400. https://doi.org/10.1177/0884533615620350.CrossRefPubMed

52.

Zhang X, Zhao Y, Zhang M, Pang X, Xu J, Kang C, et al. Structural changes of gut microbiota during berberine-mediated prevention of obesity and insulin resistance in high-fat diet-fed rats. PLoS One. 2012;7(8):e42529. https://doi.org/10.1371/journal.pone.0042529.CrossRefPubMedPubMedCentral

53.

Tanaka J, Fukuda Y, Shintani S, Hori K, Tomita T, Ohkusa T, et al. Influence of antimicrobial treatment for helicobacter pylori infection on the intestinal microflora in Japanese macaques. J Med Microbiol. 2005;54(3):309–14. https://doi.org/10.1099/jmm.0.45814-0.CrossRefPubMed

54.

Griffiths EA, Duffy LC, Schanbacher FL, Qiao H, Dryja D, Leavens A, et al. In vivo effects of bifidobacteria and lactoferrin on gut endotoxin concentration and mucosal immunity in Balb/c mice. Dig Dis Sci. 2004;49(4):579–89. https://doi.org/10.1023/B:DDAS.0000026302.92898.ae.CrossRefPubMed

55.

Wang ZT, Yao YM, Xiao GX, Sheng ZY. Risk factors of development of gut-derived bacterial translocation in thermally injured rats. World J Gastroenterol. 2004;10(11):1619–24. https://doi.org/10.3748/wjg.v10.i11.1619.CrossRefPubMedPubMedCentral

Title: The beneficial effects of the composite probiotics from camel milk on glucose and lipid metabolism, liver and renal function and gut microbiota in db/db mice
Authors: Tabusi Manaer
Lan Yu
Xin-Hua Nabi
Dinareer Dilidaxi
Lu Liu
Jialehasibieke Sailike
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Escherichia Coli
Probiotics
Metformin
Respiratory Microbiota
Published in: BMC Complementary Medicine and Therapies / Issue 1/2021
Electronic ISSN: 2662-7671
DOI: https://doi.org/10.1186/s12906-021-03303-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The beneficial effects of the composite probiotics from camel milk on glucose and lipid metabolism, liver and renal function and gut microbiota in db/db mice

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Quality of complementary and alternative medicine information for type 2 diabetes: a cross-sectional survey and quality assessment of websites

Synergistic antifungal evaluation of over-the-counter antifungal creams with turmeric essential oil or Aloe vera gel against pathogenic fungi

Crude extract and isolated bioactive compounds from Notholirion thomsonianum (Royale) Stapf as multitargets antidiabetic agents: in-vitro and molecular docking approaches

Targeting the hallmarks of cancer: the effects of silibinin on proliferation, cell death, angiogenesis, and migration in colorectal cancer

Efficacy and safety of Kami-guibi-tang for mild cognitive impairment: a pilot, randomized, double-blind, placebo-controlled trial

Bupi Yishen formula attenuates kidney injury in 5/6 nephrectomized rats via the tryptophan-kynurenic acid-aryl hydrocarbon receptor pathway